White Papers

BD Persist™ PVP Iodine/Alcohol Prep Swabs

• Evaluation of the Application Time for Persist™ Antiseptic Solution
• Evaluation of the Activity of Persist™ Antiseptic Solution for up to 9 Days
• Comparison of Persist™ Antiseptic Activity Under OpSite™ IV3000 or Gauze Dressings
• Hill Top Study: Evaluation of the Antimicrobial Activity of Persist™ Antiseptic Solution

• Evaluation of the Fluid Path Contamination Potential of The BD Posiflow™ IV Access System

Evaluation of the Application Time for Persist™ Antiseptic Solution
Steven C. Felton, Ph.D., SM(ASCP)

Abstract: Persist™, an antiseptic solution, was evaluated to determine whether it is as effective as povidone-iodine (PVP-I) or isopropyl alcohol (IPA) skin antisepsis regimens when applied for 15, 30, 45, or 60 seconds. The Persist™ catheter site preparation solution was demonstrated to have antibacterial activity which is similar to either the PVP-I or the IPA positive control regimens. Although not statistically significant, the number of bacteria recovered after a 15 second Persist™ treatment was higher for two individuals. Until further studies are completed, a minimum 30 second application should be considered for Persist™. In contrast to PVP-I, the Persist™ solution dries quickly which may result in better compliance with catheter site preparation protocols.

View white paper

Top of Page

Evaluation of the Activity of Persist™ Antiseptic Solution for up to 9 Days
Steven C. Felton, Ph.D., SM(ASCP) and Cindi T. Wolosyn, B.S.

Abstract: Persist™, an antiseptic solution, was evaluated to determine whether it is as effective as povidone-iodine (PVP-I), isopropyl alcohol (IPA), or chlorhexidine (CHG) skin antisepsis regimens for up to nine days. The Persist™ catheter site-preparation solution was demonstrated to have antibacterial activity which is similar to the PVP-I, IPA, or the CHG positive control regimens up to and including 120 hours. At 7 and 9 days Persist™, PVP-I, IPA, and CHG appeared to decline in antiseptic activity; there was still no significant difference between the treatments. The Persist™ solution has been shown to be efficacious with a short application time and it dried quickly which may result in better compliance with catheter site-preparation protocols.

View white paper

Top of Page

Comparison of Persist™ Antiseptic Activity Under OpSite™ IV3000 or Gauze Dressings
Steven C. Felton, Ph.D., SM(ASCP) and Cindi T. Wolosyn, BS

Abstract: Persist™, an antiseptic solution, was evaluated to determine recolonization under either OpSite™ IV3000 (polyurethane dressing) or standard gauze dressings at 24, 48, and 72 hours. There were no significant differences in the bacterial recolonization rates between the dressings with either antiseptic treatment. The Persist™ solution has been shown to be efficacious with a short application time and dries quickly which may result in better compliance with catheter site preparation protocols.

View white paper

Top of Page

Hill Top Study: Evaluation of the Antimicrobial Activity of Antiseptic Solution
Hill Top Research Inc, Miamiville, OH

Abstract: Persist, an antiseptic solution, was evaluated to determine if it is as effective as the povidone iodine in glass ampules (commercially available product) for routine site preparation as demonstrated by the reduction in the number of viable bacteria recoverable from the skin surface. The study was a paired comparison design. Treatment sites were randomly assigned to test and control treatments and sampling intervals to ensure a statistical distribution. The Persist product is considered to be efficacious as a catheter site antiseptic agent having reduced the bacterial count below 12 colony forming units/square centimeter of skin at the 10 minute post-treatment sampling interval.

View white paper

Top of Page

BD Posiflow™ Luer-activated ValveEvaluation of the Fluid Path Contamination Potential of The BD Posiflow™ IV Access System
Steven C. Felton, Ph.D., SM(ASCP)

Abstract: BD Posiflow™, a needleless connector, was evaluated to determine whether the fluid path of these devices could become contaminated with bacteria in the unlikely event that bacteria were inoculated into the internal (not fluid path) space of these devices. None of the fluid paths of the 63 devices tested became contaminated during this testing. From these results, we conclude that in the unlikely event that fluid contaminated with bacteria entered into the internal space of a BD Posiflow™ valve, there is little potential for the fluid pathway to be contaminated.

View White Paper
Product Information

Top of Page